C. Savastano and F. Lombardi, “Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs: Risposta alla combinazione Lapatinib-Capecitabina in giovane paziente con recidiva di carcinoma della mammella HER2-positivo refrattario a due linee di terapia con farmaci anti-HER2”, AboutOpen, vol. 4, no. 1, pp. 162–165, Oct. 2018.